Antibody-drug conjugate
BMS Acquires Orum’s ADC ORM-6151 for AML and MDS Treatment
Bristol Myers Squibb (BMS) has made a significant move in the field of antibody-drug conjugates (ADCs) by acquiring Orum Therapeutics’ ...
New drug Enhertu shows promise for HER2-mutant lung cancer patients (IASLC WCLC 2023 Conference)
The International Association for the Study of Lung Cancer (IASLC) presented pivotal results from the DESTINY-Lung02 Phase II trial at ...
Datopotamab Deruxtecan + Imfinzi Transform First-Line NSCLC Treatment in TROPION-Lung04 Trial
The TROPION-Lung04 Phase Ib trial has unveiled highly promising results. The trial showcases the potential of datopotamab deruxtecan (Dato-DXd), in ...
BioNTech and DualityBio Advance Novel HER2-low Breast Cancer Drug to Phase III Trial
BioNTech, the renowned name behind the COVID-19 vaccine breakthrough, is venturing into uncharted territory with its licensed antibody-drug conjugate (ADC), ...
Ovarian Cancer: Upifitamab Rilsodotin Misses Primary End Point
Source – Mersana Therapeutics According to Mersana Therapeutics, the antibody-drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) did not achieve its ...
Maintaining Durable QOL in HER2+ Breast Cancer Patients: Trastuzumab Deruxtecan
Results published in Annals of Oncology indicate that Trastuzumab deruxtecan (T-DXd; Enhertu) showed superior health-related quality-of-life (HRQOL) outcomes compared to ...
FDA Approves IND for Selected Advanced Solid Tumors Using ADRX-0706
Source – Adcentrx Therapeutics The FDA has granted clearance to Adventrx Therapeutics’ IND application for ADRX-0706, a promising treatment for ...
